Latest

Ilias Zapantis reflects on recent steps taken to improve diversity in the NHS workforce and shares some of the actions AHSNs are making to improve inclusivity in the recruitment process.

A new report published today by UCLPartners and the London School of Hygiene & Tropical Medicine sets out how the health and care system should prioritise and resource rapid service evaluations, based on lessons from the pandemic.

Essex Partnership University NHS Foundation Trust have partnered with Oxehealth to improve the safety, quality and efficiency of care on their inpatient mental health wards and have reported the first insights from the evaluation. We are working with Oxehealth on a larger scale real world validation of the Oxevision platform at EPUT and supporting the technology’s adoption at other NHS Trusts.

Our Technology Evaluation Lead, Ilias Zapantis, writes about LGBT+ History Month, reflects on what it means for those who work in healthcare and shares some of the activities undertaken at UCLPartners to further knowledge and raise awareness.

UCLPartners Health Technology Advisor Gareth Cairns discusses how point of care and at home testing has come to the fore in the pandemic and looks at some examples that are proving valuable in this space.

Clinical trials conducted by UCLPartners' AHSC from 2010-2015 showed that Cladribine is an effective oral treatment for highly active MS. Since then, UCLPartners has been driving the spread and adoption of the drug in clinical practice.

A major concern for general practice is how to continue with the essential covid response while providing proactive care to patients who are at highest risk of deterioration.

David Probert has been announced as the new Chief Executive of University College London Hospitals. David replaces Professor Marcel Levi, who is stepping down at the end of March t...

Health and care services have innovated quickly in response to the pandemic. But how do we evaluate rapid implementations made at scale?

NHS England have confirmed a change in prescribing requirements for Cladribine tablets, a high efficacy oral treatment for highly active Multiple Sclerosis (MS), that will make the treatment more accessible to patients across England.